Browse result page of AntiTbPdb
The total number entries retrieved from this search are 86
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1783 | Peptide-27 | KL-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | RBC | NA | 43.6 % and 24.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1784 | Peptide-28 | F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 66 µg/mL | Both | RBC | NA | 86.8 % and 50 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1785 | Peptide-29 | GABA-F-Tic-Oic-GABA-K-Tic-Oic-GABA-F-Tic-Oic-GABA-K-Tic-KKKK | Acetylation | Amidation | GABA = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 28 µg/mL | Both | RBC | NA | 10.8 % and 1 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1786 | Peptide-30 | G-Tic-Oic-K-Tic-Oic-G-Tic-Oic-K-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 6 µg/mL | Both | RBC | NA | 26.7 % and 9.2 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1787 | Peptide-31 | GF-Oic-GK-Oic-GF-Oic-GKKKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 180 µg/mL | Both | RBC | NA | 5.9 % and 3.2 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1790 | Peptide-34 | GF-G-Oic-GK-G-Oic-GF-G-Oic-GK-G-KKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 200 µg/mL | Both | RBC | NA | 3.3 % and 3.30 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1791 | Peptide-35 | GF-F-Oic-GK-F-Oic-GF-F-Oic-GK-F-KKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | RBC | NA | 27.30 % and 8.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1792 | Peptide-36 | βAla-F-Tic-Oic-βAla-K-Tic-Oic-βAla-F-Tic-Oic-βAla-K-Tic-KKKK | Acetylation | Amidation | βAla= beta-alanine, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 1 µM or 2.5 µg/mL | Both | RBC | NA | 24.4 % and 7.4 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | Acute toxicity was observed at dose of 125 mg/kg | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1793 | Peptide-37 | Ahx-F-Tic-Oic-Ahx-K-Tic-Oic-Ahx-F-Tic-Oic-Ahx-K-Tic-KKKK | Acetylation | Amidation | Ahx = 6-amino hexanoic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 8.1 µg/mL | Both | RBC | NA | 44.7 % and 26.6 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1794 | Peptide-38 | F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-KKKKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 17 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | RBC | NA | 41.3 % and 33.5 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1795 | Peptide-39 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.8 µg/mL | Both | RBC | NA | 24.9 % and 18.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1796 | Peptide-40 | GABA-F-Tic-Oic-GABA-K-Tic-Oic-GABA-F-Tic-Oic-GABA-K-Tic-KKKKK | Acetylation | Amidation | GABA = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 8.1 µg/mL | Both | RBC | NA | 29.7 % and 10.5 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1797 | Peptide-41 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Orn-Orn-Orn-Orn | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Orn = Ornithine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1798 | Peptide-42 | G-Fpa-Tic-Oic-GK-Tic-Oic-G-Fpa-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Fpa = 4-fluorophenylalanine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1799 | Peptide-43 | GF-Tic-Oic-G-Orn-Tic-Oic-GF-Tic-Oic-G-Orn-Tic-Orn-Orn-Orn-Orn | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Orn = Ornithine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1800 | Peptide-44 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Biotinylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 26 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1801 | Peptide-45 | GF-Tic-Oic-G-Dpr-Tic-Oic-GF-Tic-Oic-G-Dpr-Tic-Dpr-Dpr-Dpr-Dpr | Acetylation | Amidation | Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 220 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1802 | Peptide-46 | βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-Dpr-Dpr | Acetylation | Amidation | βAla = beta-alanine, Fpa, 4-fluorophenylalanine, Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 228 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1803 | Peptide-47 | G-f-Tic-Oic-GK-Tic-Oic-G-f-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | Mix | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1804 | Peptide-48 | GF-Tic-Oic-G-k-Tic-Oic-GF-Tic-Oic-G-k-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | Mix | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1805 | Peptide-49 | G-Nph-Tic-Oic-GK-Tic-Oic-G-Nph-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Nph = 4-nitrophenylalanine, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 25 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1884 | Trichoderins A | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC = 0.1 μg/mL | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1885 | Trichoderins A | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 0.02 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1886 | Trichoderins A | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37RV | MIC = 0.12 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1887 | Trichoderins A1 | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium smegmatis | Mycobacterium smegmatis M341 | MIC = 1.56 μg/mL | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1888 | Trichoderins A | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 0.16 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1889 | Trichoderins A1 | PXXXIVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37RV | MIC = 2.0 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1890 | Trichoderin B | PXXXVVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium smegmatis | Mycobacterium smegmatis M341 | MIC = 0.63 μg/mL | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1891 | Trichoderin B | PXXXVVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 0.02 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1892 | Trichoderin B | PXXXVVXX | Addition of MDA (2-methyl decanoic acid) | Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol) | Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8 | Cyclic | 8 | D | NA | Natural | Isolated from Trichoderma species 05FI48 | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37RV | MIC = 0.63 μg/ml | In vitro | NA | Tratment with this concentration inhibit 100% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2010 | 20483615 |
| antitb_1920 | Peptide-5 | GF(A6c)G(A6c)Dpr(A6c)G(A6c)F(A6c)G(A6c)GDpr(A6c) Dpr-Dpr-Dpr- Dpr | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Dpr = 2,4-diaminopropanoic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 24.63 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1924 | Peptide-9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 20.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1931 | Peptide-5 | GF(A6c)G(A6c)Dpr(A6c)G(A6c)F(A6c)G(A6c)GDpr(A6c) Dpr-Dpr-Dpr- Dpr | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Dpr = 2,4-diaminopropanoic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | MIC = 49.26 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1935 | Peptide-9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | MIC = 20.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1942 | Peptide-5 | GF(A6c)G(A6c)Dpr(A6c)G(A6c)F(A6c)G(A6c)GDpr(A6c) Dpr-Dpr-Dpr- Dpr | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Dpr = 2,4-diaminopropanoic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR | MIC = 49.26 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1946 | Peptide-9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 20 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR | MIC = 20.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |